WHO Grade 3 Glioma Recruiting Phase 1 Trials for Nivolumab (DB09035)

Also known as: WHO Grade III Gliomas / Grade III Glioma / WHO Grade III Glioma

IndicationStatusPhase
DBCOND0146359 (WHO Grade 3 Glioma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04323046Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsTreatment